Swiss Biotech Windward Files for US IPO

Windward Bio, a Basel, Switzerland-based biotech, filed for a US IPO on October 23, 2026. The company plans to list on Nasdaq under the ticker WWB. It has secured up to $365 million from investors including Novo Holdings, OrbiMed, Omega Funds and Blue Owl Healthcare Opportunities. Novo Holdings holds a 14.5% pre-IPO stake and Blue Owl-managed funds hold a 5.9% stake. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are the underwriters. Lead candidate WIN378 targets TSLP for severe asthma and COPD and is in Phase 2/3 for asthma and Phase 2 for COPD. Early-stage candidate WIN027 targets TSLP and IL-13 for inflammatory conditions including atopic dermatitis and is in Phase 1. One report said the company plans to raise up to $100 million, though final offering terms have not been disclosed. The company is seeking funds to advance clinical trials.






